Drugs / LY2140023
LY2140023
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT03321617 | Apr 2018 → Mar 2020 | — | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT02919774 | Oct 2016 → Apr 2018 | — | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT02234687 | Sep 2014 → Feb 2016 | post-traumatic stress disorder | NYU Langone Health | Terminated | No outcome recorded |
| Phase 1 | NCT01659177 | Aug → Sep 2012 | — | Denovo Biopharma LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT01637142 | Jul 2012 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01606436 | Jun → Aug 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01609218 | Jun → Sep 2012 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01591330 | Apr → Jun 2012 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01524237 | Apr 2012 → Jul 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01475136 | Nov 2011 → Dec 2012 | liver disorder | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01440478 | Sep → Oct 2011 | — | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01354353 | May 2011 → Mar 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT01125358 | May 2010 → Sep 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01086748 | Mar 2010 → May 2012 | schizophrenia | Denovo Biopharma LLC | Completed | Missed primary |
| Phase 2 | NCT01052103 | Jan 2010 → Jun 2012 | schizophrenia | Denovo Biopharma LLC | Completed | Missed primary |
| Phase 2 | NCT00845026 | Mar 2009 → May 2010 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00520923 | Sep 2007 → Oct 2008 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00149292 | Aug 2005 → Jul 2006 | schizophrenia | Denovo Biopharma LLC | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01129674 | Jun 2010 → Oct 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | No outcome recorded |
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT01487083 | Dec 2011 → Oct 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01452919 | Nov 2011 → Sep 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 3 | NCT01328093 | Apr 2011 → Oct 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | Met primary |
| Phase 3 | NCT01307800 | Mar 2011 → Sep 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2012-08-29 | Eli Lilly and Company | Results Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results lilly.com ↗
The decision was made after a recently conducted independent futility analysis concluded HBBN, the second of Lilly's two pivotal studies, was unlikely to be positive in its primary efficacy endpoint if enrolled to completion. |
| 2012-07-11 | Eli Lilly and Company | Results Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study lilly.com ↗
In study HBBM, pomaglumetad methionil did not separate from placebo in the primary efficacy endpoint in either the overall or predefined genetic subpopulation (based on the Positive and Negative Syndrome Scale, PANSS) at the two doses investigated (40 mg and 80 mg BID). |
| 2009-03-29 | Eli Lilly and Company | Results Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research lilly.com ↗
The primary analyses did not demonstrate that any of the four LY2140023 monohydrate doses (5, 20, 40 and 80 mg taken twice daily) separated from placebo. |
| 2007-09-02 | Eli Lilly and Company | Results Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds lilly.com ↗
The study demonstrated that: -- LY2140023 and olanzapine showed statistically significant improvement versus placebo in PANSS (Positive and Negative Syndrome Scale), the most common scale used for measuring symptoms of patients with schizophrenia. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-11 | Denovo Biopharma LLC | Denovo Biopharma Announces Partnership with Orygen on Phase 2 Study Evaluating DB103 (Pomaglumetad Methionil) in Treating Psychosis denovobiopharma.com ↗ |
| 2012-08-29 | Eli Lilly and Company | Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results lilly.com ↗ |
| 2012-07-11 | Eli Lilly and Company | Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study lilly.com ↗ |
| 2009-03-29 | Eli Lilly and Company | Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research lilly.com ↗ |
| 2007-09-02 | Eli Lilly and Company | Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds lilly.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2140023 | “The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in...” NCT02919774 ↗ |
| Known as | LY2140023 Monohydrate | “Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.” PMID 24772351 ↗ Mar 2014 |
| Known as | POMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02919774 ↗ |
| Known as | pomaglumetad | “We conducted an exploratory analysis of the existing clinical trial database of pomaglumetad methionil (pomaglumetad) to demonstrate treatment response in targeted patient populations.” PMID 25890643 ↗ Mar 2015 |
| Known as | pomaglumetad methionil | “The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in...” NCT02919774 ↗5“Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.” PMID 24772351 ↗ Mar 2014 “existing clinical trial database of pomaglumetad methionil (pomaglumetad) to demonstrate treatment response in targeted patient populations.” PMID 25890643 ↗ Mar 2015 |
| Action | Activate | “a receptor agonist that modulates the glutamatergic activity” NCT00149292 ↗ |
| Route | Oral | “Administered orally” NCT00520923 ↗ |